Apoptotic cell removal or interactions of early stage apoptotic cells with immune cells are associated with an immunomodulatory microenvironment that can be harnessed to exert therapeutic effects.
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Prospects of apoptotic cell-based therapies for transplantation and inflammatory diseases
Philippe Saas [1] [2] [3] [4] , Sandra Kaminski [1] [2] [3] [4] , Sylvain Perruche Drugs and biotherapies are not devoid of side effects and improvements in patient treatment are needed. Indeed, biological agents, such as anti-TNF, have significantly improved the treatment of inflammatory chronic diseases, such as rheumatoid arthritis (RA). However, 30 to 40% of RA patients are considered to be refractory or contraindicated to these agents. In solid organ transplantation settings, acute graft rejection is now significantly controlled by immunosuppressive drugs. In contrast, the benefits of such immunosuppressive drugs on chronic rejection and overall long-term graft survival are still uncertain. Allogeneic hematopoietic cell transplantation is an efficient immunotherapy to cure leukemia. However, this approach is associated with major life-threatening complications, notably graft-versus-host disease (GvHD) which occurs in 30 to 80% of allografted patients. Cell-based therapies are new alternative therapeutic strategies that can be used to limit, or even, controlall these pathologies with limited toxic effects.More than ten years ago, we propose to use intravenous (iv) early apoptotic cell infusion as an alternative cell-based therapeutic approach in allogeneic hematopoietic cell transplantation, initially conceptually [1] , and then experimentally [2] .
In this review, we will introduce immunomodulatory mechanisms associated with early apoptotic cells. Then, we will report and discuss data obtained in preclinical experimental models, before proposing future perspectives for such therapeutic approach.
Immunomodulatory properties associated with early apoptotic cells
 An immunosuppressive/anti-inflammatory microenvironment created by the apoptotic cell death Apoptosis is a cell death mechanism occurring in different physiological situations, including development, or during normal cell turn over with elimination of unwanted or undesirable cells. For instance, more than half of the cells are eliminated by apoptosis in the mammalian brain during development [3] . More than one hundred billion of neutrophils die daily by apoptosis [3] . Elimination of apoptotic neutrophils by macrophages following tissue injury−a process called efferocytosis [4] − is critical for the resolution of inflammation,as well as initiation of tissue repair [5] . In all these situations, apoptotic cells are quickly removed after apoptosis has been triggered [6] . This elimination takes place before the apoptotic cells become completely dislocated [6] , and is estimated to occur less than 3 hours after the apoptotic signal initiation [7] . This suggests initially that apoptotic cell death is a silent immune mechanism [8, 9] . Apoptotic cells are preferentially uptaken by professional phagocytes, such as macrophages [10] [11] [12] [13] [14] [15] [16] , microglia in the brain [17] [18] [19] [20] ,and/or some dendritic cells (DC) subsets [14, 15, [21] [22] [23] . Secretion of TGF-β after apoptotic cell removal by macrophages [11, 31] ,microglia [27] or conventional DC [31]hasalsobeen described. Secretion of these anti-inflammatory cytokines can occur spontaneously after apoptotic cell encounter or is observed after stimulation with Danger signals mimicked in vitro by TLR ligands (LPS or zymosan, for TLR4 and TLR2, respectively) ( Table 1) . Regulatory factors other than immunosuppressive cytokines, such as retinoid acid [32] , prostaglandin-E2 (PGE2) [11, 27] , enhanced tryptophan catabolism via stimulation of indoleamine 2,3-dioxygenase (IDO) enzymatic activity [33, 34] ,and/or specialized proresolving lipid mediators (e.g., resolvins) [35] , are also produced by professional phagocytes eliminating apoptotic cells (Figure 2 ). Thus, immunosuppressive cytokine-independent mechanisms induced by apoptotic cells have been also reported [33] [34] [35] [36] [37] [38] . For instance, nitric oxide (NO) is spontaneously produced by mouse macrophages after interactions with early apoptotic cells [37, 38] .
This prevents the release of MIP-2, the murine homolog of IL-8, which plays a role in neutrophil recruitment [38] . Synthesis of NO after apoptotic cell removal by murine macrophagesinhibitsalso the production of the chemokine KC [37] . Moreover, uptake of apoptotic cells by professional phagocytes is associated with a decreased capacity to produce pro-inflammatory cytokines, including :TNF, IL-1β,   IL-6, IL-8,GM-CSF, IL-12 or IL-23[11, 20, 23, 28, 31, 39-41], or inflammatory factors, such as,reactive oxygen species (Figure 2) . Again, as observed for anti-inflammatory cytokines, decrease of proinflammatory factor synthesis can occur spontaneously after apoptotic cell interactions in pathological situations where pro-inflammatory cytokine production is exacerbated. Prior apoptotic cell removal prevents also ex vivopro-inflammatory cytokine secretion by TLR stimulation (Table 1) .A decrease of pro-inflammatory cytokine secretion after apoptotic cell exposure can be a direct effect on pro-inflammatory cytokine genes, independent of IL-10 and TGF-β Marginal zone macrophages of the spleen are specialized in the uptake of blood-borne apoptotic leukocytes [12, 13] . In addition, marginal zone macrophages can secrete after apoptotic cell removal CCL22 to recruit specifically Treg [57] .Recent data describe the relationship between dedicated antigen-presenting cell (APC) subsets and the induction of pTreg, one of the main mechanisms involved in peripheral tolerance. This is true for macrophage subsets in the lung [58] In addition to professional phagocytes, non-professional phagocytes (i.e., neighboring cells) can also uptake apoptotic cells ( Table 2 ). The process of apoptotic cell removal by amateur phagocytes is usually slower [70] [71] [72] , requires apoptotic cells in a more advanced stages [70] and is limited to subcellular fragments (i.e., a smaller "prey") rather than whole dying cells [71, 73] . Secondary necrosis due to delayed or impaired apoptotic cell removal leads to the release of toxic intracellular compounds that corresponds to Danger signals, named damage-associated molecular patterns (DAMP) [74] . These DAMP activates APC that, in turn, initiate efficient T cell responses through Th1, Th2 or Th17 differentiation profile. Moreover, in certain conditions, pro-inflammatory chemokines(e.g., IL-8, MCP-1/CCL2 and RANTES/CCL5) are released by these non-professional phagocytes [75, 76] , leading to inflammatory cell recruitment. On the other hand, in certain tissues where professional phagocytes have limited access in steady state (e.g., the retina or the kidney), neighbor amateur phagocytes participate efficiently to the quiet elimination (i.e., without inflammation) of apoptotic cells [77, 78] .Thus, depending on the cells involved in apoptotic cell removal and on the speed/kinetics of this removal, apoptotic cells may block or initiate immune responses. One has to evoke the status of another APC that interacts with T cells: plasmacytoid dendritic cells (PDC), a particular DC subset that differ from conventional DC(for review [79] ). No doubt exists that PDC can uptake dying cell materials [80, 81] , as almost each cell type seems to be able to do it ( Table 2) .It remains to be determined whether PDC correspond to real professional or non-professional phagocytes.Several arguments suggest that PDC are non-professional phagocytes, including:i) delayed apoptotic cell elimination [82] , ii) subcellular fragment uptake as attested by endocytosis of apoptotic cell-derived membrane microparticles or apoptotic bodies [82, 83] but not whole apoptotic cells [84, 85] , iii) the release of pro-inflammatory cytokines (e.g., IFN-α, IL-6) [83, 86] .
However, despite limited capacity to uptake apoptotic cells, PDC may play a role in apoptotic cellinduced immunomodulationby interacting with other immune cells: macrophage and pTreg [84] . Indeed,apoptosis was initially defined morphologically[101],but differentbiochemical pathwaysin response to different apoptotic stimuli lead to diverse apoptotic cell deaths with distinct immune consequences (tolerance versus immunogenicity)(for review on molecular definitions of apoptotic cell death, please refer to [102] ; please also refer to a review dealing with immunogeneic and tolerogeneic cell death [103] ). In a recent review [104] , the5 factors evoked above were called the 5
Ws of dying cells (for:Who, Where, Why, What and When). This enables to predict the immunological outcome of apoptotic cell death.Considering apoptotic cell-based therapy to limit inflammation and control undesirable immune responses, the following criteriahave been selected: early apoptotic mononuclear cells (i.e., mainly lymphocytes), intravenous infusion to target preferentially splenic professional phagocytes(marginal zone DC and/or macrophages that deal each day with billions of dying leukocytes), and induction of tolerogenic apoptosis (see next paragraph).
Preclinical data using early apoptotic cell infusion in experimental models
As discussed in the first part of this review, apoptotic cells are able to modulate the functions of several immune cells, including: macrophages, DC, NK cells, or CD4 + T cells. The functions of these cells are deregulated in several inflammatory or autoimmune diseases. This is the case, for instance, of deregulated inflammatory cytokinesecretion in sepsis or in RA.Based on their immunomodulatory or transient immunosuppressive properties described above, apoptotic cell administration has been performed in different experimental models of inflammatory and/or immune disorders (Table 3) .
From these studies, it is possible to better understand how apoptotic cells interact with the immune system, but also to proposethe design of future clinical approaches. In this part of the review, we will analyze the different preclinical studies (Table 3) to select critical parameters to exert therapeutic effects, or in the contrary, to exclude factors that lead to no or opposite effects. Most of the studies report the prevention of the disease; that means that, apoptotic cells were infused at the triggering of the disease (i.e., at immunization with auto-antigens, or at time of transplantation) or before the disease occurred. This is true for: type 1 diabetes in NOD mice [47] , experimental autoimmune encephalomyelitis (EAE) [12, 62, 105] , arthritis[36, 106, 107] , fulminant hepatitis [108] , contact hypersensitivity [109] [110] [111] , acute and chronic graft rejection [85, [112] [113] [114] , hematopoietic cell engraftment [2, 14, 84, 115, 116] , acute graft-versus-host (GvHD) disease [14] and reduction of infarction size after acute myocardial infarction [117, 118] . Thus, it is difficult to transpose this in the clinical setting where, in general, the disease is already present when a therapeutic solution has to be found. Nevertheless, one may propose that apoptotic cell infusion can be useful in disease prevention associated with a high risk of morbidity/mortality, such as GvHD (please refer to a recent review on the use of apoptotic cells in allogeneic hematopoietic cell transplantation [119] ), a high risk of graft rejectionor in prevention of diabetes in the pre-diabetic stage. The use of apoptotic cell infusion in the prevention of complications associated with transplantation (i.e., graft rejection or GvHD) is conceivable, since, in general, the transplantation process is scheduled, and so, apoptotic cell infusion can be performed before or at time of the transplantation, before the complications occurs. However, it is difficult to apply to cadaveric solid organ transplantation where the transplantation procedure is not predictable. Moreover, apoptotic cell administration has also been tested in experimental models to treat ongoing active diseases (as in the "real life"), such as acute heart graft rejection [114] , chronic GvHD(our unpublished data) or sepsis [91, 120] . This latter pathology is interesting, since administration during the disease protects mice from sepsis-induced death [91, 120] ,while infusion 5 days before sepsis worsens mice survival, possibly by decreasing the capacity to secrete IFN-γ[121]. Thus, this opens the way to use apoptotic cell administration to cure ongoing diseases, such as acute graft rejection or chronic GvHD without specific side effects (e.g., auto-antibody production) [122] .
How clinical trials using apoptotic cells should be designed? In other words, we will now address from the experimental data the critical parameters for the future clinical studies, namely: i) the route of administration; ii) the number (schedule) of administration; iii) the adequate apoptotic cell typeto be used and the apoptotic signal. Most of the studies (91%, 20 out of 22) used the intravenous (iv) route of administration (Table 3) . Consequently, the spleen and its marginal zone APC (lymphoid resident CD8α + DC[62, 85, 114] , B cells [105, 106] or macrophages [12, 14, 84] ) are critical for the modulation of the immune responses, since the spleen is the main filter for blood-borne apoptotic cells [123] . In contrast, 4 studies reportedapoptotic cell infusion either intra-peritoneally (ip) [106, 107] , intra-tracheally [91] or intra-myocardially [118] . Some studies compared these routes of administration and iv route;no difference was observed [106, 118] . These particular routes were evaluated, since the diseases were induced through the same routes [91, 107] . Thus, this may theoretically present the advantage of targeting the affected organ (e.g., the myocardium [118] , the lung or the peritoneum [91] ) without generating a systemic effect. Apoptotic cell-based therapies can be useful to treat systemic diseases, and in this case, the iv route has to be preferred. On the other hand, this approach can be used in local diseases by injecting closed to the affected organs/tissues. (Table 3) . So, one may speculate that some diseases need tolerance induction against pathogenic auto-or allo-antigens while other implicate a non-specific down-regulation of inflammation or transient immune suppression (Figure 3 ). In line with this hypothesis, splenic macrophages [14, 120] or liver Kupffer cells [108] have been shown to play a critical role in diseases modulated by the anti-inflammatory effects of apoptotic cell infusion, whereas splenic conventional DC −that are more critical for antigen presentation to T cells than macrophages [29, 51, 52]− are necessary for tolerance to donor allo-or auto-antigens[62, 85, 110, 111, 114] . Some of these studies evaluated functionally the role of APC phagocyting infused apoptotic cells by in vivo depletion using either clodronate loaded liposomes [14, 84] , gadolinium chloride [108, 113] or transgenic mice expressing diphtheria toxin receptor under the control of macrophage-or DC-specific promoterrendering macrophages or DC sensitive to diphtheria toxin administration [12, 62, 85] . In addition, ex vivo functionsof macrophages were also tested after apoptotic cell infusion with reduced secretion of pro-inflammatory cytokine secretion, such as TNF [107] (see also (Figure 3) .
In a practical point of view, preclinical models are useful to determine antigen dependency as reported in Table 3 . Then, if a disease requires a particular antigen, this antigen needs to be expressed by the apoptotic cells, or at least locally present when apoptotic cells are eliminated. This leads to select cells from a particular origin (e.g., the donor in the case of transplantation) or to engineer patient PBMC to express a nominal antigen as performed in autoimmune diseases [12, 62] .
In contrast, if the disease does not need any specific antigen and is treated independently of apoptotic cell origin, PBMC can be obtained from healthy volunteers after written informed consent and a bank of PBMC can be established. Alternatively, PBMC can be obtained from the patienthimself. This later solution is the simplest, even if no lymphopenia, leukemic cells or infections are present.
The cumulative encouraging data obtained in preclinical models allow physicians to initiate clinical studies. This is particularly true for the prevention of acute GvHD. Acute GvHD−an inflammatory disorder associated with allogeneic hematopoietic cell transplantation−is due to the activation of host APC by the conditioning regimen that, stimulates donor allogeneic T cells. These activated allogeneic T cells as well as factorsreleased during this process (e.g., TNF) destroy healthy tissues from the recipients including: the liver, the gastro-intestinal tract and the skin [124] . In experimental models (Table 3) (Table 3) .
Conclusion
In conclusion, early apoptotic cell infusion has been reported to treat or prevent experimental inflammatory/autoimmune disorders, as well as complications associated with transplantation (Table   3) . A phase 1/2a clinical trial has been performed in 13 patients without specific toxicities and a good early outcome [126] . This confirms the feasibility of such cell-based therapy approach in Humans.
Today, the major questions concern:i) the interactions of such therapy with other treatments received by patients,as for instance steroids (that increase apoptotic cell removal by macrophages immunosuppressive drugs routinely used in allogeneic hematopoietic cell transplantation and rapamycin (sirolimus) has a synergic effect [115] . This kind of study has to be extended to other conventional drugs, such as steroids, or methotrexate for RA. Concerning other side effects (autoimmunity or global immunosuppression), careful selection and follow-up of patients may limit these effects. As performed for anti-TNF, patients with active or ongoing infections or a past of cancer should be excluded. In order to prevent autoimmune disease related to impaired apoptotic cell removal, factors known to play a role in this clearance such as C1q have to be analyzed before patient enrolment. Finally, instead of infusing apoptotic cells, apoptotic cell death may be induced in vivo using different approaches (i.e., CD3 specific antibody [31]) and tolerance can be achieved with similar mechanisms (for review [119] ).
Future perspectives
How the fields described here (i.e., the use of apoptotic cells and the understanding of mechanisms involved in apoptotic cell removal) will evolve in the next 5 to 10 years? We speculate that several phase 1/2a studies and even phase 2 studies, will be performed in different autoimmune diseases or in the settings of transplantation. Other therapies will be derived from this approach to focus on the main mechanism(s) or factor(s) responsible for the therapeutic effects. For instance, apoptotic cell secretome (that is the factor released by cells undergoing apoptosis) has been shown to exert similar effect on acute myocardial infarction than apoptotic cell infusion [130] . Liposomes expressing phosphatidylserines mimicking an "eat-me" signal associated with anti-inflammatory properties [11, 91] can also be infused in the femoral vein to improve acute myocardial infarction [131] .These two recent publications [130, 131] confirm that the non-specific anti-inflammatory function of apoptotic cell infusion is sufficient to limit acute myocardial infarction. Phosphatidylserine-expressing liposomes are not a cell-based product. This has the advantage of being controlled or produced at large scale using pharmaceutical procedures and not to be dependent on cell therapy regulations.Other perspectives are linked to improvements performed in the understanding of APC subsets and on the characterization of receptors and ligands involved in apoptotic cell removal. One may imagine that the identification of receptor(s) expressed by tolerogeneic professional phagocytes would be preferentially targeted to restore tolerance and cure inflammatory auto-or allo-immune diseases.
Executive summary:
Introduction  Improvement of existing treatment is needed for severalinflammatory and/or immunemediated disorders, including transplantation, acute or chronic inflammatory diseases by modulating the deregulated immune response.
Immunomodulatory properties associated with early apoptotic cells  Apoptotic cells themselves, elimination of apoptotic cells by innate immune cells or interactions of these cells with apoptotic cells lead to an immunomodulatory microenvironment that may
favor or restore tolerance.
 Several factors govern theseimmunomodulatory properties and mechanisms involved in this process are currently being deciphered.
Preclinical data using early apoptotic cell infusion in experimental models
 Intravenous early apoptotic cell infusion can be used for disease prevention, notably in diseases associated with high mortality/morbidity, for instance, acute graft-versus-host disease.
 Intravenous apoptotic cell infusion can be used for disease treatment, such as, sepsis or acute graft rejection.
 Critical aspectsto consider to achieve a beneficial therapeutic effect include: i) the iv route of administration, but local administration (into the myocardium, lung or peritoneum) is also possible; ii) one infusion is often sufficient; iii) blood leukocytes is the easiest and major source of apoptotic cells; iv) a tolerogenic apoptotic signal inducing early apoptotic cells is required (e.g., γ-or UVB-irradiation).
 The analysis of mechanisms involved in these experimental models suggests that iv apoptotic cell infusion acts by two distinct mechanisms: i)modification of the inflammatory microenvironment by targeting professional phagocytes and ii)induction of "specific" tolerance to a given antigen throughregulatory cell commitment in the favorable microenvironment shaped by the professional phagocytes. No writing assistance was utilized in the production of this manuscript.
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We are grateful to Sarah Odrion for her help in editing our manuscript, to Prof Dror Mevorach (Hadassah University, Jerusalem, Israel) for helpful discussionsand the sharing of the clinical data as well as the members of our laboratory for their work. human monocyte-derived macrophages ↑ TGF-β, ↑ PGE-2, ↓TxB2, ↓LKTC4 (spontaneously) ↑ TGF-β, ↓ GM-CSF, IL-1β, IL-8, IL-10, TNF-α (LPS, TLR4 ligand) ↑ TGF-β, ↓ GM-CSF, IL-10, TNF (zymosan, TLR2 ligand) [11] human monocyte-derived macrophages; human macrophage cell line RAW264.7; murine macrophage cell line J774
Tables
↓ IL-12 p35mRNA, ↓ IL-12 (IFN-γ + LPS). These effects are independent of IL-10 and TGF-β.
[39]
murine peritoneal macrophages; human monocytes; human monocytederived macrophages; human macrophage cell line RAW264.7
↑ IL-10 (spontaneously), but difference exists between the phagocyte tested IL-10 was the sole cytokine studied.
[25]
murine peritoneal macrophages ↑ TGF-β in vitro and ex vivo (in vivo exposure) (spontaneously) TGF-β was the sole cytokine studied. rat microglial cells ↑ TGF-β, HGF (spontaneously) ↓ NO, PGE-2, TNF, no effect on IL-10 (LPS)
[27] Adapted from Ref. [152] . Some of these factors are produced spontaneously after apoptotic cell encounter or increased or diminished after a subsequent stimulation by TLR ligands in the context of inflammation (see Table 1 ). *Concerning NO synthesis, differences existbetween human and muse macrophages [153] and maybe also between in vivo and in vitro conditions [154] . Abbreviations used:
AhR, aryl hydrocarbon receptor; GM-CSF, granulocyte and macrophage colony stimulating factor; HGF, hepatocyte growth factor; IL, interleukin; IL-1RA, interleukin-1 receptor antagonist; iNOS, inducible nitric oxide synthase; LT4C, leukotriene C4; NGF, nerve growth factor; NO, nitric oxide; NOS2, nitric oxide synthase-2; PAF, platelet-activating factor; PGE-2, prostaglandin-E2, RvE, resolvin E; TXA2, thromboxane A2; VEGF, vascular endothelial growth factor A.↓, decrease; ↑, increase; see also text. Figure 2 ), localized to the site where the cells are dying and/or being eliminated (i.e., the spleen after iv infusion), and non-specific (i.e., all the cells sensitive to immunosuppressive cytokines at the site of apoptotic cell removal are affected). Experimental models of pathological disorders have been shown to respond to this anti-inflammatory effect, including arthritis, sepsis, fulminant hepatitis, allogeneic hematopoietic cell engraftment,or acute myocardial infarction (see text). In contrast, apoptotic cellinduced tolerance is related to antigen (Ag)-specific regulatory cell induction. This antigen-specific tolerance may persist (according to the life span of the induced pTreg) and may not be restricted to the site of apoptotic cell clearance (depending on the migratory properties of the generated pTreg).
Experimental models of pathological diseases, such as: type 1 diabetes, EAE, contact hypersensitivity, prevention or treatment of acute graft rejection, prevention of chronic graft rejection or of acute GvHD (aGvHD) have been shown to require infusion of apoptotic cells bearing specific auto-or donor allo-antigen(s). After iv infusion, splenic macrophages are rather involved in anti-inflammatory effect of apoptotic cells, whereas splenic lymphoid resident conventional DC are implicated in tolerance induction.
